ESCMID抗生素过敏评估与管理临床指南
该指南由欧洲临床微生物与感染病学会制定,采用改良GRADE-ADOLOPMENT流程,基于4部2022至2023年指南及系统检索证据,为报告抗生素过敏的患者提供结构化临床评估与去标签推荐,旨在减少误标并促进抗菌药物合理使用。
要点
- 仅约5%至10%的报告抗生素过敏为真正免疫介导的超敏反应。
- 误标可导致避免一线抗生素、增加广谱药物使用及耐药风险。
- 推荐结构化评估反应特征,低可能性者可行直接去标签或药物激发试验。
核心结论
- 报告抗生素过敏中仅少部分为真正免疫介导超敏反应,误标可促进抗菌药物耐药。
- 推荐结构化临床评估,低可能性者行直接去标签或对照药物激发试验。
研究设计与样本
- 由16名感染病、过敏、药学、儿科和临床微生物学专家组成多学科小组制定。
- 采用改良GRADE-ADOLOPMENT流程,系统检索PubMed和Trip Database(2015-2023)及原始研究(2021-2024)。
- 纳入4部符合AGREE全球评级量表方法学质量标准的2022至2023年指南。
- 推荐经迭代工作与共识流程形成,最终共识定义为≥80%成员同意。
主要发现
- 报告抗生素过敏中仅约5%至10%估计为真正免疫介导超敏反应。
- 误标可导致不必要避免一线抗生素、增加广谱药物使用及药物毒性等并发症。
关键数值与推荐
- 推荐结构化临床评估,考虑索引反应特征。
- 临床病史提示真过敏可能性极低或低时,适合直接去标签或进行对照药物激发试验。
临床怎么用
- 面向非过敏专科临床医生,旨在统一欧洲及以外医疗机构的实践。
- 通过支持过敏评估和审慎处方,改善患者结局并强化抗菌药物管理目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SCOPE: Antibiotic allergies remain one of the most frequently documented drug allergies in clinical records. It is well established that only a small proportion-estimated at 5% to 10%-represents true immune-mediated hypersensitivity. Mislabelling can contribute to the development of antimicrobial resistance via prescription of suboptimal antimicrobial therapy (i.e. unnecessary avoidance of first-line antibiotics), increased use of broad-spectrum agents, and complications such as drug toxicity. This guideline, developed by the European Society of Clinical Microbiology and Infectious Diseases, provides evidence-based recommendations for the clinical evaluation and management of patients with reported antibiotic allergies. It is aimed at nonallergist clinicians and seeks to harmonize practice across healthcare settings in Europe and beyond. METHODS: The guideline was developed by a multidisciplinary panel of 16 experts in infectious diseases, allergy, pharmacy, paediatrics and clinical microbiology, following a modified GRADE-ADOLOPMENT process. Systematic searches were conducted in PubMed and the Trip Database (2015-2023) to identify relevant guidelines, complemented by an additional systematic search for primary studies (2021-2024). The included guidelines were assessed using the AGREE Global Rating Scale. Four existing guidelines, from 2022 and 2023, met methodological quality criteria and were included. Key questions were identified and prioritized by the panel, and relevant data were extracted using piloted Evidence to Decision framework sheets. The panel developed recommendations by adopting, adapting or formulating new recommendations, through an iterative work-up and consensus process. All recommendations were finalized through panel discussion and formal voting, with consensus defined as agreement by ≥ 80% of members. RECOMMENDATIONS: The guideline recommends a structured clinical assessment to evaluate a reported antibiotic allergy, taking into consideration the characteristics of the index reaction. Where the clinical history suggests a very low or low likelihood of true allergy, direct delabelling or performing a controlled drug challenge test is appropriate. By supporting allergy evaluation and prudent prescribing practices, the recommendations aim to improve individual patient outcomes and reinforce antimicrobial stewardship goals.
引用
- Joean O, Sermet K, Ashkenazi-Hoffnung L, et al. ESCMID clinical guidelines on the evaluation and management of a reported antibiotic allergy. Clin Microbiol Infect. 2026. PMID: 41707748. doi:10.1016/j.cmi.2026.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。